RASP — Actavia Life Sciences Income Statement
0.000.00%
Last trade - 00:00- $6.02m
- $6.23m
Annual income statement for Actavia Life Sciences, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 0 | — | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.915 | 5.43 | 0.236 | -0.141 | 4.24 |
| Operating Profit | -0.915 | -5.43 | -0.236 | 0.141 | -4.24 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.944 | -5.35 | -0.876 | -0.687 | -4.44 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.936 | -5.35 | -0.876 | -0.687 | -4.44 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.936 | -5.35 | -0.876 | -0.687 | -4.44 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.936 | -5.35 | -0.876 | -0.687 | -4.44 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.014 | -0.033 | -0.013 | -0.011 | -0.008 |